tiprankstipranks
Trending News
More News >
Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
India Market
Advertisement

Bliss Gvs Pharma Limited (BLISSGVS) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

BLISSGVS Financial Forecast

BLISSGVS Earnings Forecast

The previous quarter’s earnings for BLISSGVS were ₹4.08.
The previous quarter’s earnings for BLISSGVS were ₹4.08.

BLISSGVS Sales Forecast

The previous quarter’s earnings for BLISSGVS were ₹2.07B.
The previous quarter’s earnings for BLISSGVS were ₹2.07B.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on IN:BLISSGVS
TR | OpenAI - 4o
TR | OpenAI - 4o
₹176₹200
Hold
28.21%
Upside
Reiterated
07/31/25
AI Generated ArticleAI Generated Article
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on IN:BLISSGVS
TR | OpenAI - 4o
TR | OpenAI - 4o
₹176₹200
Hold
28.21%
Upside
Reiterated
07/31/25
AI Generated ArticleAI Generated Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BLISSGVS Analyst Recommendation Trends

Rating
Jul 25
Strong Buy
0
Buy
0
Hold
5
Sell
0
Strong Sell
0
total
5
In the current month, BLISSGVS has received 0 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BLISSGVS average Analyst price target in the past 3 months is 167.00.
Each month's total comprises the sum of three months' worth of ratings.

BLISSGVS Stock Forecast FAQ

What is IN:BLISSGVS’s average 12-month price target, according to analysts?
Based on analyst ratings, Bliss Gvs Pharma Limited’s 12-month average price target is 167.00.
    What is IN:BLISSGVS’s upside potential, based on the analysts’ average price target?
    Bliss Gvs Pharma Limited has 7.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Bliss Gvs Pharma Limited a Buy, Sell or Hold?
          Bliss Gvs Pharma Limited has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Bliss Gvs Pharma Limited’s share price target?
            The average share price target for Bliss Gvs Pharma Limited is 167.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹167.00 ,and the lowest forecast is ₹167.00. The average share price target represents 7.05% Increase from the current price of ₹156.
              What do analysts say about Bliss Gvs Pharma Limited?
              Bliss Gvs Pharma Limited’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of Bliss Gvs Pharma Limited?
                To buy shares of IN:BLISSGVS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis